Lytic Lesions + Hypercalcemia in Hematological Conditions: Differentials

1. Multiple Myeloma (PRIMARY and most common)

• Myeloma cells secrete MIP-1α (CCL3) and upregulate RANKL while simultaneously suppressing OPG - this shifts the RANKL/OPG ratio strongly toward osteoclast activation
• Myeloma cells also produce Wnt pathway inhibitors that block osteoblast function, creating a purely lytic pattern with no new bone formation
• Net result: massive uncoupled osteolysis, hypercalcemia, and pathologic fractures
• (Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 570; Goldman-Cecil Medicine, RANKL/OPG section)

• "Punched-out" lytic defects, classically 1-4 cm, with no surrounding sclerosis (the absence of reactive new bone is characteristic)
• "Moth-eaten" appearance in long bones; calvaria lesions are highly characteristic

Lateral radiograph of distal femur showing moth-eaten lytic lesions in multiple myeloma - Frameworks for Internal Medicine

Classic "punched-out" lytic lesions in the skull (lateral view) - Robbins, Cotran & Kumar

2. Adult T-Cell Leukemia/Lymphoma (ATLL) - HTLV-1 Associated

• Driven by HTLV-1 (most prevalent in Japan and the Caribbean basin)
• Patients present with circulating disease, bone marrow involvement, hypercalcemia, lytic bone lesions, lymphadenopathy, hepatosplenomegaly, skin lesions, and opportunistic infections
• Pathognomonic: "flower cell" (CD4+, CD25+, CD2+, CD3+, CD5+, CD7-)
• 4 variants: acute (worst, median survival 6 months), lymphomatous, chronic, smoldering
• (Harrison's Principles of Internal Medicine 22E, 2025)

3. Non-Hodgkin Lymphoma (NHL)

4. Leukemias (less common, but recognized)

• AML (acute myeloid leukemia) - rare but reported
• CLL - uncommon, but B-cell infiltration of bone can produce lytic change
• Mechanism involves locally produced osteoclast-activating cytokines including PTHrP, IL-1, IL-6, and IL-8
• (Brenner & Rector's The Kidney - Malignancy section)

Summary Table: Hematological Differentials

Key Differentiating Lab Workup

1. SPEP/UPEP + immunofixation - M-protein = myeloma/plasmacytoma
2. Serum free light chains - kappa/lambda ratio
3. PTH - suppressed in all malignancy-related hypercalcemia
4. PTHrP - elevated in ATLL, some NHL; low in myeloma
5. 1,25(OH)₂D (calcitriol) - elevated in lymphoma-related hypercalcemia
6. HTLV-1 serology - ATLL
7. Bone marrow biopsy - plasma cell % (myeloma), T-cell immunophenotype (ATLL)
8. Skeletal survey / Whole body low-dose CT - distribution and morphology of lytic lesions

• CRAB = the four cardinal myeloma manifestations (Calcium, Renal, Anemia, Bone)
• The absence of bone scan uptake (cold lesions) in myeloma vs. hot lesions in metastatic carcinoma is a classic radiological differentiator

Lytic Lesions + Hypercalcemia in Hematological Conditions: Complete Differential (Hematologist Level)

TIER 1 - Plasma Cell Dyscrasias (Most Likely)

1. Multiple Myeloma

• Bone scan is characteristically cold (purely lytic, no reactive new bone = no osteoblast activity = no uptake) - use skeletal survey or PET/CT/whole-body low-dose CT instead
• RANKL↑ / OPG↓ ratio is the core pathophysiologic driver
• IgG (52%) > IgA (21%) > light chain only (16%) > IgD (2%) > IgE (rare) - IgD and IgE myelomas have disproportionately high rates of plasma cell leukemia transformation
• Bones affected descending: vertebrae > ribs > skull > pelvis > femur > clavicle > scapula
• Robbins, Cotran & Kumar; Harrison's 22E (2025)

2. Solitary Plasmacytoma of Bone

3. Plasma Cell Leukemia (PCL)

• Diagnostic threshold: >5% plasma cells in peripheral blood differential and/or absolute plasma cell count ≥500/µL
• Primary PCL (60%): de novo presentation in leukemic phase - younger patients, more hepatosplenomegaly, lymphadenopathy, higher platelet count, fewer bone lesions, smaller M-protein, but better survival than secondary PCL
• Secondary PCL (40%): leukemic transformation of known myeloma - older patients, more bone disease, rapidly fatal
• Immunophenotype: unlike typical myeloma, CD56 is often absent in PCL
• IgD (12%) and IgE (25%) myelomas are over-represented among PCL transformations
• Hypercalcemia present due to same RANKL/osteoclast mechanism
• Treatment: aggressive induction (VDT-PACE or daratumumab-VRd) → ASCT if response achieved
• Goldman-Cecil Medicine; Harrison's 22E; Robbins Cotran

4. Nonsecretory Myeloma

• 3% of myeloma cases - no detectable M-protein in serum or urine by SPEP/UPEP/immunofixation
• Bone lesions and hypercalcemia are present and identical to secretory myeloma
• Diagnosis relies on bone marrow biopsy with immunoperoxidase/flow cytometry confirming clonal plasma cells
• Serum free light chain (sFLC) assay is abnormal in >60% - this is the key monitoring tool
• Pitfall: can be missed if sFLC not ordered; the clinician must have high suspicion when CRAB features present but standard protein studies are negative
• Goldman-Cecil Medicine

5. POEMS Syndrome (Osteosclerotic Myeloma)

• Hypercalcemia and renal insufficiency are rare in POEMS (key differentiator from myeloma)
• Bone marrow usually has <5% plasma cells
• The diagnosis is confirmed by biopsy of a sclerotic lesion showing monoclonal plasma cells
• If lesions are limited: radiation therapy (>50% neuropathy improvement)
• If widespread: ASCT or systemic therapy
• Goldman-Cecil Medicine

TIER 2 - Lymphoid Malignancies

6. Adult T-Cell Leukemia/Lymphoma (ATLL) - HTLV-1 Driven

• The hematologist must ask about origin: Japan, Caribbean basin, West Africa, Middle East - HTLV-1 endemic regions
• Hypercalcemia in ATLL is mediated by PTHrP secreted by malignant T-cells, often dramatically elevated, can reach severe levels (>14 mg/dL)
• Lytic lesions + hypercalcemia + flower cells on smear = pathognomonic triad
• CD4+, CD25+, CD2+, CD3+, CD5+, CD7- (the CD7 loss is a key negative)
• FOXP3+ (resembles regulatory T-cells - contributes to profound immunosuppression)
• Skin involvement: erythroderma, nodules, papules (not just rash - actual leukemic skin infiltration)
• Opportunistic infections mirror AIDS because CD4 cells are dysfunctional despite being numerous
• Acute form: survival 6 months; treatment with zidovudine + interferon-α ± arsenic, mogamulizumab (anti-CCR4)
• Harrison's Principles of Internal Medicine 22E (2025)

7. Non-Hodgkin Lymphoma (NHL) with Bone Involvement

• Direct bone marrow infiltration → cytokine-mediated osteoclast activation (PTHrP, IL-1, IL-6, IL-8)
• Lytic lesions on imaging; PTH suppressed, PTHrP may be elevated
• Less commonly produces discrete punched-out defects (more permeative/infiltrative pattern)

• Malignant lymphocytes express 1α-hydroxylase (same enzyme as granulomatous macrophages)
• Converts 25(OH)D → active 1,25(OH)₂D without PTH regulation
• Lab pattern: PTH suppressed ↓, PTHrP normal, serum 1,25(OH)₂D elevated ↑
• This is the most important distinguishing lab from myeloma (where calcitriol is NOT elevated)
• Can occur even without direct bone involvement
• All types of lymphoma can cause this syndrome
• (Brenner & Rector's The Kidney; Frameworks for Internal Medicine)

8. Hodgkin Lymphoma (HL)

• Lytic bone lesions and hypercalcemia occur but are less common than in NHL/myeloma
• Mechanism primarily ectopic 1,25(OH)₂D production (same as NHL above)
• Bone involvement in HL is usually part of stage IV disease
• Lytic lesions in HL can cause cord compression, pathologic fractures
• Key clinical point: HL is one of the few metastatic bone diseases that is potentially curable even with bone involvement - must not be mistaken for myeloma and written off as palliative
• (Harrison's 22E; Goldman-Cecil)

TIER 3 - Histiocytic Neoplasms

9. Langerhans Cell Histiocytosis (LCH)

• "Punched-out" lytic lesions of the skull - can resemble myeloma radiologically
• CT shows sharp, well-defined lytic defect with beveled edges (geographic lysis)
• Preferential involvement of the calvaria, mandible, and temporal bone (causes aural polyp, conductive hearing loss, postauricular swelling)
• Hypercalcemia occurs but is less prominent than in myeloma
• Key differentiator: age (children/young adults), Birbeck granules on EM, CD1a+ / CD207 (Langerin)+ / S100+ on IHC
• BRAF V600E mutation - has therapeutic implications (vemurafenib responsive)
• (Goldman-Cecil Medicine; Robbins & Kumar Basic Pathology; Grainger & Allison's Diagnostic Radiology)

TIER 4 - Rare/Advanced Differentials (Complete the Hematologist's List)

10. Erdheim-Chester Disease (ECD)

• Non-Langerhans cell histiocytosis (CD68+, CD163+, CD1a-, S100-)
• BRAF V600E in ~54% of cases
• Bilateral and symmetrical long bone involvement (femora, tibiae, humeri) - the PET-CT pattern is distinctive (bilateral periosteal uptake)
• Lytic lesions less common than sclerotic lesions, but mixed patterns occur
• Hypercalcemia can occur
• Retroperitoneal fibrosis ("hairy kidney"), periaortic cuffing, diabetes insipidus, xanthelasma are hallmarks
• (Goldman-Cecil Medicine - described as a differential to LCH in the same section)

11. Hemophagocytic Lymphohistiocytosis (HLH) secondary to hematological malignancy

• Bone marrow infiltration by underlying lymphoma/leukemia triggers the syndrome
• Hypercalcemia via direct bony involvement + cytokine storm (IL-6, TNF-α)
• Context: ferritin >10,000, fever, splenomegaly, cytopenias, hypofibrinogenemia, elevated sCD25

Master Comparison Table (Hematologist Reference)

Diagnostic Algorithm - Hematologist Approach

Lytic lesion(s) + Hypercalcemia
│
├── Check PTH → Suppressed in ALL malignancy-related causes
│
├── SPEP/UPEP + Immunofixation + sFLC ratio
│   ├── M-protein present → Plasma cell dyscrasia spectrum
│   │   ├── Multiple lesions + CRAB → MULTIPLE MYELOMA
│   │   ├── Single lesion, no systemic disease → SOLITARY PLASMACYTOMA
│   │   ├── >5% plasma cells in blood → PLASMA CELL LEUKEMIA
│   │   ├── No M-protein on SPEP but sFLC abnormal → NONSECRETORY MYELOMA
│   │   └── Sclerotic lesions + neuropathy + λ-chain → POEMS
│   │
│   └── No M-protein → Consider lymphoid or histiocytic cause
│       ├── Check PTHrP elevated? → ATLL, some NHL
│       ├── Check 1,25(OH)₂D elevated? → NHL, Hodgkin lymphoma
│       ├── HTLV-1 serology positive + flower cells → ATLL
│       ├── Lymph node biopsy / PET-CT → NHL / Hodgkin
│       └── Young patient + skull/temporal lytic lesions → LCH (CD1a, BRAF)
│
└── Bone marrow biopsy in all cases

Key Calcium Mechanism Summary for Exams & Boards

L-Asparaginase Allergy: How to Proceed

Step 1 - Classify the Reaction First

Key Pearl: Silent inactivation is more common than overt hypersensitivity and is associated with a negative clinical outcome in high-risk ALL because the enzyme appears to be given but is actually not working. Measuring serum asparaginase activity (SAA) is the only way to detect this.

Step 2 - Immediate Management of the Acute Reaction

1. Stop the infusion immediately
2. Administer:
   • Epinephrine (for anaphylaxis: 0.01 mg/kg IM, max 0.5 mg)
   • IV antihistamines (diphenhydramine)
   • IV corticosteroids (hydrocortisone or methylprednisolone)
   • IV fluids; oxygen; bronchodilators as needed
3. Observe for minimum 1-2 hours post-reaction
4. Document the reaction grade per CTCAE criteria (Grade 1-4)
5. Check serum asparaginase activity level - if reaction occurred after a previous dose, retroactively check if prior doses had adequate activity

Step 3 - The Formulation Switch Strategy

The Three Formulations

The Decision Tree

Patient develops hypersensitivity or silent inactivation to:
│
├── NATIVE E. COLI asparaginase
│   └── Switch to PEGASPARGASE (PEG-asparaginase)
│       (PEG coating reduces immunogenicity: <20% develop antibodies)
│
├── PEGASPARGASE (first-line) → allergic reaction
│   └── Switch to ERWINIA asparaginase (Erwinaze / JZP458)
│       (Completely different bacterial source = no cross-reactivity)
│       - Dose: 25,000 IU/m² IM 3× per week (Mon/Wed/Fri)
│         OR 25,000 IU/m² IV over 1 hour 3× per week
│       - Activity window is SHORT (t½ ~16h), hence the 3×/week dosing
│
├── ERWINIA asparaginase → shortage/unavailable
│   └── JZP458 (recombinant Erwinia-derived, produced in Pseudomonas)
│       - Approved 2021; closes the "asparaginase allergy gap"
│       - Produced recombinantly, not dependent on bacterial fermentation → 
│         addresses supply shortage problem
│       [Blood, 2023 - PMID 36795447]
│
└── Allergic to ALL formulations (very rare)
    └── Asparaginase discontinuation as LAST RESORT
        - Intensify other components of regimen (consult protocol-specific guidance)
        - Do NOT simply omit without expert hematology/oncology discussion

Step 4 - Why Cross-Reactivity Does NOT Occur Between Species

• Pegaspargase and native E. coli asparaginase: Both derived from E. coli - share the same protein epitopes. Antibodies raised against one will cross-react with the other. If pegaspargase causes hypersensitivity, switching to native E. coli asparaginase is not an option - both will be inactivated.
• Erwinia chrysanthemi asparaginase: Derived from a completely different organism with different protein structure and epitopes. Anti-E. coli asparaginase antibodies do not bind Erwinia enzyme. This is why the switch works.

Step 5 - Key Additional Considerations

Premedication Before Subsequent Doses

• Antihistamines (cetirizine or diphenhydramine)
• Acetaminophen
• Low-dose corticosteroids

Therapeutic Drug Monitoring (TDM) - Asparaginase Activity Levels

• Target serum asparaginase activity (SAA): ≥0.1 IU/mL at nadir (trough)
• Check SAA ~72 hours after E. coli preparations, ~7 days after pegaspargase
• If SAA <0.1 IU/mL (even without clinical reaction) = silent inactivation = switch formulation immediately
• (Future Oncology, Burke & Zalewska-Szewczyk, 2022 - PMID 35107320)

Managing Other Asparaginase Toxicities (Not Allergy)

Summary Algorithm

L-Asparaginase allergy/silent inactivation confirmed
         │
         ▼
    Measure SAA → if <0.1 IU/mL = inactivation confirmed
         │
         ▼
    Identify source: E. coli-derived (native or PEG)?
         │                          │
    Yes: SWITCH to              Already on Erwinia?
    ERWINIA asparaginase              │
         │                     Yes: Use JZP458 (recombinant Erwinia)
         ▼                          or asparaginase discontinuation
    Continue ALL protocol            as absolute last resort
    with Erwinia dosing
    (25,000 IU/m² 3×/week IM or IV)
         │
         ▼
    Monitor SAA 72h post-dose → target ≥0.1 IU/mL
    Continue TDM throughout course

The Core Principle: E. coli Cross-Reactivity

The Answer Depends on the Scenario

Scenario A: Patient reacted to native E. coli L-asparaginase

• The PEG conjugation significantly reduces immunogenicity
• Less than 20% of patients develop antibodies to pegaspargase vs. much higher rates with native E. coli form
• Goodman & Gilman explicitly states: "In hypersensitive patients [to native E. coli], pegaspargase is a safe and effective alternative"
• This switch is well-supported and widely practiced

Scenario B: Patient reacted to pegaspargase itself

• The antibodies raised against pegaspargase will still recognize and neutralize any E. coli-derived asparaginase, including calaspargase pegol
• Giving pegaspargase again risks anaphylaxis or guaranteed silent inactivation
• The only correct move here is Erwinia asparaginase (Erwinaze / JZP458/crisantaspase) - completely different bacterial source, no cross-reactivity

Decision Table

Why This Distinction Matters Clinically

• The patient was started on native E. coli asparaginase (older protocol, resource-limited setting)
• The allergy occurred during the older native formulation phase before PEG was introduced

One More Critical Point: Silent Inactivation